JERUSALEM--(BUSINESS WIRE)--BioLineRx Ltd. (TASE:BLRX), today announced positive interim results from an ongoing Phase 2 trial of BL-1020, a GABA enhanced antipsychotic. The study is an open-label, multi-center, 6-week trial conducted in hospitalized patients with treatment resistant schizophrenia, in which BL-1020 showed statistically significant efficacy with minimal side effects. The assessment was part of a planned review by an Independent Safety Monitoring Board (ISMB) that reviewed the first 20 schizophrenic patients that completed 21 days of the study.
